The results of pilot trial ALL-REZ-MВ-2014 for children with relapsed acute lymphoblastic leukemia

Дьяконова, Ю. Ю.; Быданов, О. И.; Miakova, Natalia; Абугова, Ю. Г.; Алейникова, О. В.; Arakaev, Oleg; Бойченко, Э. Г.; Дубровина, М. Э.; Евстратов, Д. А.; Литвинов, Д В; Ольшанская, Ю. В.; Ponomareva, Natalia; Popov, A. M.; Potapenko, L.A.; Рогов, А В; Румянцева, Ю. В.; Фоминых, В. В.; Хачатрян, Л. А.; Карачунский, А. И.; Рб, Республиканский научно-практический центр детской гематологии и онкологии Минздрава; больница, Екатеринбург Областная детская клиническая; No, Санкт-Петербург Детская городская больница; России, Фгбу «Российская детская клиническая больница» Минздрава; больница, Ставрополь Краевая детская клиническая

doi:10.24287/1726-1708-2017-16-3-7-14

Cited by 5 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Дмитрия Рогачева. Подробное описание протокола и состав блоков ПХТ приведены нами в предыдущих публикациях [6,7]. Пациенты получали 1 курс (2 ребенка получили 2 курса) блинатумомаба в качестве salvage-терапии в том случае, если не была достигнута морфологическая ремиссия или отмечался высокий уровень МОБ перед ТГСК.…”

Section: материалы и методы исследованияunclassified

“…Схема представлена на рисунке 3. Подробное описание протокола и состав блоков полихимиотерапии также приведены нами в предыдущих публикациях [6,7].…”

Section: пациентыunclassified

“…Впоследствии, как при реализации любого цитотоксического действия, CD3 + -Т-лимфоцит, активированный блинатумомабом, освобождается от CD19 + -клетки-мишени и имеет возможность вступить в следующий цитотоксический контакт с несущей CD19 + -маркер клеткой, вызывая и ее гибель. Имеются данные, что CD19 + -фрагмент молекулы блинатумомаба обладает большей аффинностью в сравнении с CD3 + -фрагментом, что может обусловливать высокую эффективность препарата даже при низком количестве CD3 + -лимфоцитов [4][5][6][7][8]. Механизм действия блинатумомаба представлен на рисунке 1.…”

unclassified

See 2 more Smart Citations

The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience

Vavilova

Dyakonova

Быданов

et al. 2023

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Despite remarkable improvements in the treatment of pediatric acute lymphoblastic leukemia over last years, relapse still carries a poor prognosis with considerable morbidity and mortality. New immunotherapeutic approaches will change the way we treated our patients and the results we had. Blinatumomab is a bispecific T-cell-engaging antibody indicated for the treatment of relapsed/refractory B-cell lymphoblastic leukemia. The use of Blinatumomab in relapsed B-cell ALL has shown promising effects, especially as a bridging tool to hematopoietic stem cell transplantation. The therapy results for patients in the high risk group remain far from optimal due to refractoriness to chemotherapy, death from infectious complications, as well as acute chemotherapy toxicity. This article demonstrates the results of our experience of using Blinatumomab in children with the high-risk group relapsed B-cell ALL treated according to the ALL-REZ 2016 protocol. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology. The efficacy and toxicity of innovational blocks with the use of fludarabine and clofarabine with subsequent Blinatumomab infusion are shown. And we present the efficacy of autologous CD3+ lymphocytes infusion once a week during the continuous blinatumomab therapy. Also we demonstrate the results of using Blinatumomab for the treatment of patients with refractory to the first line therapy relapsed B-lymphoblastic leukemia and patients with a second relapse of B-cell ALL. The first line therapy in these patients was carried out according to the ALL-REZ 2014 protocol. Our results show an improved reduction in minimal residual disease in patients with refractory relapsed B-cell ALL as well as an increased event free survival in children with the high-risk group relapsed B-cell ALL.

show abstract

Section: материалы и методы исследованияunclassified

Section: пациентыunclassified

unclassified

See 1 more Smart Citation

The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience

Vavilova

Dyakonova

Быданов

et al. 2023

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

show abstract

“…В результате данного исследования в случае применения неларабина у всех пациентов с ТI-вариантом лейкемии была достигнута ремиссия; более чем у 80% пациентов проведена алло-ТГСК, а бессобытийная выживаемость (БСВ) составила 50%. У пациентов с вариантом TIV лишь в 40% случаев зарегистрирована полная ремиссия, а БСВ не превысила 20% [16]. Эти выводы легли в основу стратификации терапии Т-ОЛЛ в зависимости от иммунофенотипа.…”

Section: фгбу «национальный медицинский исследовательский центр детскunclassified

“…В настоящее исследование за период с 01.08. 16 Диагностику рецидива ОЛЛ во всех случаях проводили общепринятыми методами -путем цитологического и цитохимического исследований мазков костного мозга с морфологической оценкой согласно FAB-критериям. Иммунофенотипирование бластных клеток в костном мозге при диагностике и отслеживании MRD выполняли на проточном цитометре согласно стандартным процедурам; иммунологические варианты ОЛЛ определяли по стандартным лабораторным протоколам.…”

Section: материалы и методы исследованияunclassified

First results of pilot protocol ALl-REZ-2016 for children with high risk groups of relapsed acute lymphoblastic leukemia

Дьяконова¹,

Мякова²,

Litvinov³

et al. 2019

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

show abstract

A pharmacoeconomic study of pegaspargase in the treatment of pediatric acute lymphoblastic leukemia in Russia

Avxentyev

Frolov

Makarov

et al. 2022

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

Pegaspargase is an L-asparaginase that is conjugated to monomethoxypolyethylene glycol. It is currently approved for use in children and adults for acute lymphoblastic leukemia (ALL) in the Russian Federation, is included in the recommendations of clinical practice guidelines and is recommended for inclusion in the Vital and Essential Drug List. The aim of this research is to perform a pharmacoeconomic analysis of pegaspargase in the treatment of pediatric patients with ALL in the Russian healthcare setting. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of the Ministry of Healthcare of the Russian Federation. The target population of the study were pediatric patients with intermediate-risk ALL (according to the Moscow-Berlin protocol) who had not previously received treatment. We compared two treatment scenarios: therapy according to the Moscow-Berlin protocol with and without pegaspargase. A decision tree model was used to analyze the costs of ALL treatment strategies. The costs of first-line therapy, relapse therapy (in accordance with the ALL-REZ-MB-2014 protocol), hematopoietic allogenic stem cell transplantation, and third-line therapy with blinatumomab (in patients with B-cell ALL) were considered. Costs were calculated separately for patients receiving different treatments and were weight-averaged according to the total number of intermediate-risk patients. The size of the target population was determined by the incidence of ALL in 2020 and risk group distribution data obtained from the Moscow-Berlin protocol study. The costs were calculated for a cohort of patients available for therapy in 2023. The use of pegaspargase leads to a decrease in the average discounted cost of therapy for children with intermediate risk ALL of 93,273 rubles due to a decrease in the need for costly relapse therapy. Estimates show that up to 418 new patients are diagnosed with intermediate-risk ALL annually and belong the target population of this study. If 100% of ALL patients receive pegaspargase on the third day of remission induction therapy, the total cost of therapy for the target patient population will decrease by 38.99 million rubles. The use of pegaspargase on the third day of remission induction therapy in children with intermediate-risk ALL leads to a reduction in the relapse rate (superior efficacy) and lower costs, compared with the treatment regimen without pegaspargase.

show abstract

The results of pilot trial ALL-REZ-MВ-2014 for children with relapsed acute lymphoblastic leukemia

Cited by 5 publications

References 0 publications

The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience

The role of blinatumomab in the treatment of B-cell relapses of acute lymphoblastic leukemia in children: own experience

First results of pilot protocol ALl-REZ-2016 for children with high risk groups of relapsed acute lymphoblastic leukemia

A pharmacoeconomic study of pegaspargase in the treatment of pediatric acute lymphoblastic leukemia in Russia

Contact Info

Product

Resources

About